Consortium project totaling $7.8 million to develop foundational technology to position bioelectrochemistry as commercially viable for difficult challenges such as CO₂ conversion
SEATTLE, Sept. 30, 2025 /PRNewswire/ — Arzeda, The Protein Design Company™, today announced it has been selected to lead a highly competitive U.S. National Science Foundation (NSF) award under the Ideas Lab: Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (NSF CFIRE) initiative. The award, totaling approximately $7.8 million, will harness Arzeda’s Intelligent Protein Design Technology™ to develop electricity-powered enzyme cascades for sustainable chemical production. This award complements Arzeda’s NSF USPRD selection announced a couple weeks ago, together advancing AI-designed enzymes and cell-free manufacturing.
“Electricity-driven biology unlocks a new manufacturing paradigm,” said Alexandre Zanghellini, Ph.D., cofounder and CEO of Arzeda and Principal Investigator on the award. “With AI-designed enzymes that run directly on electrons, we can bypass many limitations of living cells and build cleaner, more efficient routes for difficult-to-synthesize critical chemicals like methanol.”
Transforming Bioelectrochemistry
Collaborative Ecosystem
Under the award, Arzeda will lead a consortium of academia and industry, including Missouri University of Science and Technology and Novonesis A/S [OTC: NVZMY], a global leader in industrial enzyme manufacturing. The multidisciplinary team will integrate AI enzyme design, synthetic chemistry, and electrochemical engineering to advance cell-free bioelectrodes for industrial adoption.
NSF Acknowledgment
Research reported in this release is supported by the U.S. National Science Foundation: NSF CFIRE award #2453663. Any opinions, findings, and conclusions or recommendations expressed are those of the authors and do not necessarily reflect the views of the NSF. NSF award announcement: https://www.nsf.gov/tip/updates/nsf-invests-more-32m-biotechnology-accelerating-adoption.
About Arzeda
Arzeda develops innovative products powered by its Intelligent Protein Design Technology™, using generative AI-driven design to create, validate, and manufacture new proteins and enzymes that enhance our lives and protect our planet. We commercialize with Fortune 500 go-to-market partners across multiple industries, enabling higher-performing, more cost-effective solutions that are healthier and sustainable. For more information, please visit www.arzeda.com.
Media Contact
pr@arzeda.com
SOURCE Arzeda
Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…
PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…
IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…
CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…
The Life Sciences BPO Market is expanding rapidly, driven by rising R&D costs, increasing regulatory…
Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…